Omeros (OMER) Retained Earnings (2010 - 2026)
Omeros (OMER) posted Retained Earnings of $793.6 million for Q1 2026, up 186.85% sequentially from -$913.7 million in Q4 2025, and up 8.76% YoY from $729.7 million in Q1 2025.
Analysis
Omeros (OMER) Retained Earnings (2010 - 2026) Analysis & Trends
Omeros has reported Retained Earnings for 17 years, with the latest figure at $793.6 million in Q1 2026.
- Quarterly Retained Earnings rose 8.76% year-over-year to $793.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $793.6 million (up 8.76% YoY) and the FY2025 annual result came in at -$913.7 million, changed 0.37% from the prior year.
- Retained Earnings grew to $793.6 million in Q1 2026 per OMER's latest filing, from -$913.7 million in the prior quarter.
- Over five years, Retained Earnings peaked at $793.6 million in Q1 2026 and troughed at -$969.2 million in Q2 2025.
- A 5-year average of -$427.3 million and a median of -$744.5 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings jumped 214.51% in 2023, then slumped 225.06% in 2024.
- Over 5 years, Retained Earnings stood at -$635.7 million in 2022, then surged by 214.51% to $727.9 million in 2023, then plunged by 225.06% to -$910.3 million in 2024, then slipped by 0.37% to -$913.7 million in 2025, then surged by 186.85% to $793.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $793.6 million, -$913.7 million, and $779.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | -844.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -844.40 Mn |
| Mar 31, 2026 | -857.64 Mn |
| Dec 31, 2025 | -913.70 Mn |
| Sep 30, 2025 | -1.00 Bn |
| Jun 30, 2025 | -969.23 Mn |
| Mar 31, 2025 | -943.81 Mn |
| Dec 31, 2024 | -910.35 Mn |
| Sep 30, 2024 | -878.99 Mn |
| Jun 30, 2024 | -846.76 Mn |
| Mar 31, 2024 | -790.71 Mn |
| Dec 31, 2023 | -753.53 Mn |
| Sep 30, 2023 | -744.46 Mn |
| Jun 30, 2023 | -706.71 Mn |
| Mar 31, 2023 | -669.42 Mn |
| Dec 31, 2022 | -635.72 Mn |
| Sep 30, 2022 | -764.45 Mn |
| Jun 30, 2022 | -746.99 Mn |
| Mar 31, 2022 | -716.15 Mn |
| Dec 31, 2021 | -683.13 Mn |
| Sep 30, 2021 | -963.76 Mn |